Republican House appropriators have set up a spending battle with the Democrat-controlled Senate by setting fiscal 2025 spending targets for discretionary funding lower than previously agreed to -- a move also raising alarms among health stakeholders Thursday (May 16).
FREE TRIAL Receive 30 days of no-obligation access. SIGN UP
Home
Breaking Telehealth News
Energy & Commerce Substitute Bill Calls For Two-Year Telehealth Extension, Adds PBM, Clinical Lab Offsets
The House Energy & Commerce Committee filed substitute amendments Wednesday (May 15) for several of the 23 health bills scheduled for a health subcommittee markup Thursday (May 16), including one that scales back an earlier bill that had called for a permanent extension of certain Medicare telehealth flexibilities to just two years and adds pharmacy benefit manager reforms and Medicare clinical laboratory payment cuts as pay-fors.
Top Story
Whitehouse, Cassidy Unveil Primary Care Payment Reform, Related RFI
Provider organizations are celebrating a physician payment reform bill Sens. Sheldon Whitehouse (D-RI) and Bill Cassidy (R-LA) introduced Wednesday (May 15), which would create a hybrid Medicare payment system that rewards primary care providers based on patient health outcomes and reduces cost-sharing for patients who participate in certain primary care activities and services.
Latest News
Senate health committee Chair Bernie Sanders (I-VT) released data suggesting weight-loss drugs could soon cost the U.S. health system more than all other drugs combined and he is now asking Denmark to pressure Novo Nordisk to bring its U.S. prices down to those in that country, but industry experts said Thursday (May 16) using international reference pricing could backfire because it could lead to higher prices overseas.
Democrats are growing frustrated with the amount of time Republicans on the House Oversight & Investigations Select Subcommittee on the Coronavirus Pandemic are spending scrutinizing the actions of officials at the National Institutes of Health (NIH), they said at a hearing Thursday (May 16), claiming it has pulled attention away from more important issues of pandemic prevention.
A top official at FDA’s Center for Biologics Evaluation and Research (CBER) says the lack of an exemption under the Inflation Reduction Act (IRA) drug negotiation program for drugs approved for multiple rare diseases is shifting drug developers’ focus and could result in less investment in the rare disease space, in an unusual FDA comment on one of the Biden administration’s chief legislative achievements and a favorite target of Republicans and the pharmaceutical industry.
MORE TOP STORIES
MORE NEWS
DOCUMENTS
© 2002-2024. Inside Washington Publishers | Contact Us